Home  |  Contact
Due to work on this service, it may not be fully operational on Wednesday March 20 between 1.30 pm and 2.30 pm CEST. Apologies for the inconvenience.

UniProtKB/Swiss-Prot Q5IJ48: Variant p.Pro116Leu

Protein crumbs homolog 2
Gene: CRB2
Chromosomal location: 9q33-q34
Variant information

Variant position:  116
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Polymorphism
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Proline (P) to Leucine (L) at position 116 (P116L, p.Pro116Leu).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Similar physico-chemical property. Both residues are medium size and hydrophobic.
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  116
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  1285
The length of the canonical sequence.

Location on the sequence:   CVPGFQGPRCELDIDECASR  P CHHGATCRNLADRYECHCPL
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         CVPGFQGPRCELDIDECASRPCHHGATCRNLADRYECHCPL

Mouse                         CVPGFQGPHCELDIDECASRPCQHGGTCQNLADHYECHCPL

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 29 – 1285 Protein crumbs homolog 2
Domain 108 – 144 EGF-like 2; calcium-binding
Disulfide bond 112 – 123
Alternative sequence 1 – 332 Missing. In isoform 3.


Literature citations

Characterization of the crumbs homolog 2 (CRB2) gene and analysis of its role in retinitis pigmentosa and Leber congenital amaurosis.
van den Hurk J.A.J.M.; Rashbass P.; Roepman R.; Davis J.; Voesenek K.E.J.; Arends M.L.; Zonneveld M.N.; van Roekel M.H.G.; Cameron K.; Rohrschneider K.; Heckenlively J.R.; Koenekoop R.K.; Hoyng C.B.; Cremers F.P.M.; den Hollander A.I.;
Mol. Vis. 11:263-273(2005)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1); TISSUE SPECIFICITY; VARIANTS LEU-46; LEU-97; LEU-116; THR-145; ALA-159; ASP-187; THR-351; GLN-534; TRP-610; ALA-709; GLN-746 AND MET-1110;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.